TORONTO, ON & MONTREAL, QC-Enigma Biomedical Group and McGill University’s Research Centre for Studies in Aging in Montreal have signed a clinical research agreement in support of multiple projects to be conducted over the next several years.
The projects will focus on an early stage imaging agent (MK-6240), to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. As part of the agreement, Enigma will not only provide funding, but will also supply the MK-6240 precursor through its U.S. entity Cerveau Technologies Inc.
NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
“We are proud to partner with McGill University Research Centre for Studies in Aging, one of the premier institutions in the world,” Lee Anne Gibbs, president of Enigma Biomedical Group said. “This is another important step in our ongoing and long-term relationship with McGill.”
“These research projects will provide valuable insight into the status and progression of NFTs in healthy subjects, subjects with mild cognitive impairment and confirmed Alzheimer’s Disease,” adds Dr. Pedro Rosa-Neto, Director of McGill University Research Centre for Studies in Aging. “We appreciate the support of Enigma Biomedical Group and value our ongoing relationship.”
Dr. Serge Gauthier, Director of the AD & Related Disorders Research Unit of the McGill University Research Center for Studies in Aging said: “The ability to visualize and quantify tau in the brain will facilitate therapeutic research in the field of Alzheimer’s disease.”